Introduction
============

Many chronic pain patients are elderly (ie, \>65 years of age) ([@b74-cia-3-421]) and a significant number of these experience chronic pain which can affect their normal functioning and quality of life ([@b30-cia-3-421]). Difficulty in assessing the quality and intensity of pain due to cognitive changes and the presence of multiple medical problems associated with aging contributes to undertreatment of pain in this population. However, pharmacokinetic and metabolic changes associated with increased age make these patients more vulnerable to the potential side effects and overdosing with analgesic agents. Therefore, management of chronic pain due to cancer or persistent neuropathic pain ([@b57-cia-3-421]; [@b28-cia-3-421]) is a challenge, especially in the growing population of elderly patients.

Chronic pain treatment in the elderly is multidimensional and includes noninvasive as well as invasive therapies. Invasive therapies include pharmacological therapies with nonopioid, opioid, and adjuvant medications. New routes of administration of drugs have opened up new treatment options for the treatment of chronic pain in the elderly ([@b37-cia-3-421]). In this context buprenorphine, a semi-synthetic, lipophilic, unique opioid analgesic, has broad clinical applications ([@b82-cia-3-421]). Buprenorphine is being used sublingually ([@b8-cia-3-421]) and intrathecally ([@b70-cia-3-421]) for the treatment of acute pain and transdermally for the treatment of chronic pain ([@b34-cia-3-421]; [@b73-cia-3-421]; [@b11-cia-3-421]; [@b53-cia-3-421]). Its long-acting analgesic property and relative safety administered in this form make it useful for the treatment of chronic pain in the elderly. This review focuses on the use of transdermal buprenorphine for the treatment of chronic pain in the elderly.

Chronic pain management in the elderly
======================================

Chronic pain increases with age ([@b18-cia-3-421]) due to increases in the incidence of diseases such as arthritis, cancer, diabetes mellitus, and cardiovascular and neurological diseases ([@b67-cia-3-421]). Detection and management of chronic pain in the elderly is often inadequate and continues to pose a challenge for practitioners ([@b86-cia-3-421]). The detection of chronic pain in the elderly can be done with a pain scoring pain system which assesses the severity of the patient's pain subjectively on a score of from 1 to 10. The detection of pain in the elderly may be complicated by the presence depression and dementia. Dementia and confusion make the assessment of pain sometimes unreliable with resultant difficulty in applying the conservative and interventional therapies in these patients.

Elderly patients with depression report more pain than those who are not depressed ([@b13-cia-3-421]), and complaints of pain may be the first sign of dementia ([@b48-cia-3-421]). Chronic pain in the elderly can be either nociceptive or neuropathic. The conservative therapies for these states include adequate nutrition, cognitive and behavioral therapies, rehabilitational pain medicine, biofeedback, relaxation, and alternative medicine techniques such as acupuncture and acupressure. Low level activity programs also can benefit the elderly physically ([@b40-cia-3-421]).

Nonsteroidal anti-inflammatory drugs are commonly used to treat nociceptive pain and inhibit prostaglandin production. Malignant pain is often treated in the elderly with opioids which can be used also for treatment of neuropathic nonmalignant pain. Due to high fat to protein ratios, opioids in the elderly should be started at doses 25%--50% lower than those used in young adults, with rescue doses limited to 5% of the total daily dose available every 4 hours ([@b1-cia-3-421]). Commonly used opioids in the elderly are oxycodone, morphine, hydromorphone, and fentanyl patch. Oxycodone is a preferred drug in the elderly since it has a short half-life and no toxic metabolites, and is available in both the short- and long-acting forms. Morphine can be used with caution, paying attention to renal insufficiency and sedation.

Common adjuvant medications for the treatment of nonmalignant neuropathic pain in the elderly include a variety of medications such as nonopioid analgesics, opioid analgesics, adjuvant medications including antidepressants, anticonvulsants, tramadol, and capsaicin. The invasive techniques include neuromodulatory or surgical interventions such as nerve blocking, spinal cord stimulation and intraspinal, implantable drug delivery, and neurodestructive interventions. It is recommended that the least invasive and simple interventions be tried first in the elderly before use of more invasive interventions.

Chronic pain control in the elderly by all these therapeutic measures is still inadequate. The recent development of transdermal buprenorphine has opened up new treatment options for treatment of chronic pain in this growing patient group. It has unique pharmacodynamics which could make it a useful analgesic in the presence of age-related cognitive, metabolic, and pharmacokinetic changes so often seen in the elderly. The pharmacokinetics of buprenorphine, especially its slow association and disassociation rate at the receptor sites, make it useful for use in the elderly ([@b87-cia-3-421]).

Pharmacodynamics of buprenorphine
=================================

Originally, buprenorphine was thought to be 25--50 times more potent by weight than morphine in an equivalent dose ([@b43-cia-3-421]), but it is now thought that buprenorphine is 75--100 times more potent than morphine ([@b77-cia-3-421]). Buprenorphine is a centrally acting partial mu agonist and a kappa and delta opioid receptor antagonist ([@b59-cia-3-421]). Buprenorphine has a high affinity for the mu receptor and a lower intrinsic activity than a full agonist mu opioid receptor agonist ([@b16-cia-3-421]). It appears that the mu agonist effect is most important for producing its analgesic results. Buprenorphine can produce near maximal mu receptor occupation, thereby decreasing mu opioid receptor availability, and replace agonist effects and alleviate withdrawal symptoms ([@b35-cia-3-421]). Buprenorphine produces stabilization of mu receptors in the submembrane level and increases the expression of mu receptors on membranes ([@b26-cia-3-421]). By affecting the mu receptor, reserve buprenrophine can enable the switch from another opioid to buprenorphine. The mu agonist effect of buprenorphine is in the form of a bell-shaped curve. In animal models, the bell-shaped analgesic dose response curve peaks at 1 mg/kg, which is below the highest dose of 32 mg/kg reported in humans.

Buprenorphine interacts with orphanin FQ/nociceptin receptor ORL-1 in the spinal cord and the brain stem. Buprenorphine activates ORL1 in the spinal cord, which appears to be analgesic. OR-1 activation in the brain stem blocks opioid analgesic responses and contributes to the partial agonist property of buprenorphine ([@b6-cia-3-421]). Buprenorphine also possesses an antihyperalgesic effect relative to clinically used mu agonists; its antihyperalgesic effects exceed its analgesic effects ([@b72-cia-3-421]; [@b50-cia-3-421]; [@b71-cia-3-421]). It is thought that the antihyperalgesic effect of buprenorphine may be related to kappa opioid receptor blockade.

Buprenorphine is associated with a long duration of action, 6--8 hours ([@b46-cia-3-421]), which has been attributed to the slow dissociation of buprenorphine from the mu receptor ([@b43-cia-3-421]). The transdermal buprenorphine formulation has a slow onset (12--24 hours) and a long duration of action (3 days) ([@b78-cia-3-421]). Increased sensitivity to the depressant actions of opioids in the elderly is well established. Fentanyl as a transdermal preparation is not recommended for used in opioid-naïve patients because of the incidence of respiratory depression ([@b80-cia-3-421]).

Clinically relevant doses of up to 10 mg of buprenorphine have shown full dose-dependent effects on analgesia with no respiratory depression ([@b21-cia-3-421]). [@b22-cia-3-421] have shown a ceiling to respiratory depression but not to analgesia over a dose range from 0.05 to 0.6 mg buprenorphine in humans This safety profile could give transdermal buprenorphine a preferred role over transdermal fentanyl for treatment of chronic pain in the elderly. In humans, there is also a less marked effect of buprenorphine binding to mu opioid receptors on gastrointestinal transit times, and indeed constipation seen in the clinic is remarkably low ([@b36-cia-3-421]).

There was initial concern that the partial agonism of buprenorphine would lead to limited analgesia and would prevent other opioids from effectively binding. It has since been shown that buprenorphine is a strong analgesic, with no ceiling effect for analgesia ([@b43-cia-3-421]; [@b12-cia-3-421]). It does not produce persistent binding of the mu receptor, which would prevent the action of other opioids in acute and chronic painful conditions ([@b84-cia-3-421]); as a result other opioids can be used for breakthrough pain in the presence of buprenorphine ([@b12-cia-3-421]).

Decreased tolerance
===================

In humans exposed to opioids, but not physically dependent on them, a study of volunteers receiving sublingual buprenorphine in ascending doses of 1 to 32 mg demonstrated no ceiling effect for its analgesia effects ([@b85-cia-3-421]). In physically dependent individuals, acute cessation of buprenorphine may lead to withdrawal symptoms that appear to be milder than those seen with morphine ([@b39-cia-3-421]). [@b88-cia-3-421] studied equal concentrations (10 μM/L) of morphine, fentanyl, and buprenorphine, and showed that buprenorphine did not induce the loss of opioid receptors from the cell surface, as did morphine and fentanyl. Buprenorphine was unable to trigger mu receptor internalization because it has a low efficacy for activating G proteins. [@b76-cia-3-421], who studied the use of transdermal fentanyl and transdermal buprenorphine in humans, found a significant increase in the mean daily dose of fentanyl over buprenorphine in this time period. The long analgesic action of buprenorphine as well as its decreased tolerance because of loss of opioid receptors from the cell surface make it suitable the treatment of chronic pain in the elderly.

Metabolism and elimination
==========================

The metabolism of buprenorphine is mediated by cytochrome P450 in the liver ([@b39-cia-3-421]). Buprenorphine is oxidized to N dealkyl buprenorphine, also called norbuprenorphine by CYP3A4. Most opioids with the exception of buprenorphine and morphine undergo oxidation, and buprenorphine and morphine undergo glucuronidation. Both buprenorphine and norbuprinorphine undergo rapid glucuronidation. The binding to glucuronic acid leads to a low bioavailability of 5% with oral buprenorphine. Norbuprenorphine is 10 times more potent than buprenorphine in causing respiratory depression. However, this respiratory depressant effect of norbuprenorphine can be antagonized by naloxone ([@b31-cia-3-421]) and also by the substance beta-flunaltrexamine. It also has a weak mu agonist effect that is seen after chronic use. Most of the concentration of norbuprenorphine has been seen in the lungs rather than in the brain ([@b60-cia-3-421]).

Buprenorphine is metabolized to glucuronide metabolites which can be hydrolyzed in the intestine to release buprenorphine again. The released buprenorphine can be reabsorbed via the enterohepatic circulation. Excretion of buprenorphine and metabolites is 70% by feces of unchanged buprenorphine, conjugated buprenorphine, and the Phase I conjugated metabolites. The other small quantity of buprenorphine-related substances is excreted in the urine ([@b11-cia-3-421]). Unconjugated buprenorphine does not appear in urine, only in stool secondary to fecal flora beta-glucuronidase ([@b17-cia-3-421]).

Age-related changes in drug kinetics and dynamics relevant to opioids
=====================================================================

The narrowing of the therapeutic index because of physiological changes in aging can alter the pharmacokinetics and pharmacodynamics of analgesics. Important changes are seen with age which can affect opioid drug kinetics and dynamics. Hepatic blood flow decreases with age and age-related changes occur in cytochromes and conjugases are. These changes can narrow the therapeutic index and increase the risk of toxicity and drug-drug interactions ([@b23-cia-3-421]). Distribution of drugs to the central nervous system (CNS) are altered with alterations in receptors and transmitters. These CNS changes can increase risk of delirium. In addition changes in renal function can be age-related.

Buprenorphine in the presence renal impairment
==============================================

Renal impairment leading to a decrease in renal excretory function is common in elderly patients due to advanced age ([@b4-cia-3-421]) or to co-morbid conditions such as diabetes or hypertension. Buprenorphine for treatment of pain can be administered in normal doses in the elderly, because it is excreted mainly in the liver ([@b10-cia-3-421]; [@b17-cia-3-421]). In contrast, most opioids have to be cleared by the kidney and so have to be used in smaller doses, or with decreased frequency or not used at all in the elderly. Though the levels of norbuprenorphine may be increased by continuous intravenous infusions of buprenorphine in renal failure ([@b79-cia-3-421]), it most likely does not produce untoward effects because of the lower potency and lower affinity of norbuprenorphine compared with buprenorphine ([@b38-cia-3-421]). Buprenorphine can be used in elderly patients with impaired renal function and chronic renal insufficiency, and in hemodialysis patients in whom its pharmacokinetics are unchanged. [@b27-cia-3-421] studied the disposition of buprenorphine and its metabolite norbuprenorphine in 10 patients with end-stage kidney disease treated with transdermal buprenorphine. The blood samples studied showed no increase in levels of buprenorphine and norbuprenorphine at up to 70 μg/hour transdermal buprenorphine. Stable analgesic effects as seen by unchanged buprenorphine plasma levels in the presence of hemodialysis were also seen in the presence of a transdermal buprenorphine patch. Its safety for use in the presence of renal impairment is a major advantage over other opioids in the elderly.

Buprenorphine in hepatic disease
================================

Buprenorphine at high doses increases liver enzymes due to accumulation within mitochondria. Liver function is important because buprenorphine is metabolized by CYP3A4, resulting in norbuprenorphine. Both are rapidly glucuronidated by UCT1A1 and UGT2B7, and these processes occur in the liver. Unconjugated buprenorphine is excreted in the bile ([@b47-cia-3-421]; [@b15-cia-3-421]).

Buprenorphine pharmacokinetics are stable in mild to moderate hepatic impairment ([@b46-cia-3-421]).

Side effects
============

Buprenorphine can cause nausea, vomiting, sedation, euphoria, papillary constriction, delayed gastric emptying, and respiratory depression. Buprenorphine in high doses can increase liver enzymes due to accumulation within mitochondria.

Sedation should be observed with the use of buprenorphine because sedatives are known to cause pharmacodynamic interactions ([@b15-cia-3-421]). In humans, dose-response studies on respiratory depressive response showed data characterized by a bell-shaped curve in which respiratory depression response increases with increasing dose of buprenorphine in the lower dose ranges ([@b84-cia-3-421]). This bell-shaped effect for respiratory depression suggests a decreased likelihood of respiratory depression with buprenorphine at higher doses, suggesting increased safety of the drug. The same bell-shaped curve has not been shown for the other buprenorphine-related mu opioid agonist effects of analgesia, euphoria, sedation, and papillary constriction ([@b43-cia-3-421]). Nausea, vomiting, and constipation can occur with buprenorphine as with other opioids; however, it has been shown that these side effects occur significantly less with buprenorphine than with morphine ([@b85-cia-3-421]).

Comparison of side effects with other opioids
=============================================

Buprenorphine appears to have a greater margin of safety than other potent opioids such as fentanyl when used to treat chronic pain. [@b21-cia-3-421] compared the respiratory effects of buprenorphine and fentanyl given intravenously in healthy human volunteers. Buprenorphine-induced respiratory depression had a maximum (ceiling) effect at doses of \>0.1 mg/70 kg ([@b21-cia-3-421]). In another study by [@b22-cia-3-421], a ceiling effect in respiratory depression, but not in analgesia, was demonstrated in a study on 20 volunteers over a weight-adjusted dose range of 0.2--0.4 mg/70 kg. The peak analgesic effect of buprenorphine was increased by doubling the dose, and the timing and magnitude of respiratory depression as seen by sedation and respiratory rate remained unchanged. Of note, its analgesic effect had no plateau. Buprenorphine may thus have full agonist effect for analgesia and a partial agonist effect for respiratory depression at mu receptors, showing a differential effect on analgesia and respiration. It appears that its respiratory effects are limited, unlike morphine and fentanyl which have been shown to have no ceiling effect for analgesia but which can cause severe respiratory depression and apnea in high doses. No detrimental effect from chronic exposure to buprenorphine has been shown on corticosensitive immune parameters ([@b20-cia-3-421]). [@b33-cia-3-421] showed that buprenorphine, unlike morphine, was not associated with immunosuppression and did not activate the hypothalamic--pituatary axis. The lack of effects on the immune system is thought to be related to its partial agonist effects.

Routes of administration
========================

Several new routes for delivery of the buprenorphine are now available and have been used to provide analgesia, including the buprenorphine/naloxone combination and transdermal buprenorphine. The parenteral forms of buprenorphine, such as subcutaneous, intramuscular, epidural, and intrathecal, have been available since 1981. Sublingual buprenorphine has a much longer half-life than parenteral buprenorphine because of sequestration in buccal and sublingual fat. Because transdermal buprenorphine is not commercially available in the US, most clinicians who use the drug often convert from intravenous/subcutaneous infusions to sublingual buprenorphine.

Buprenorphine is a lipophilic, synthetic opioid; these properties, combined with its low molecular weight, make it suitable for transdermal delivery. Average half-life is 37 hours. Its properties of high affinity and slow dissociation combined in a slow-release transdermal form can produce long-term pain relief with fewer side effects, making it suitable for treating persistent chronic pain of long duration in the elderly in whom wide swings of drug concentration are less well tolerated. Transdermal buprenorphine has a half-life of about 30 hours. Sublingual buprenorphine can be given for breakthrough pain. In a long-term study, sublingual buprenorphine was available for use as needed for control of pain (Likar and Sittle 2005).

The transdermal route is especially useful for drugs such as buprenorphine which have limited bioavailability if given orally. Transdermal buprenorphine can provide pain relief for cancer and for chronic noncancer pain ([@b53-cia-3-421]; [@b65-cia-3-421]; [@b58-cia-3-421]). Transdermal buprenorphine formulated in an adhesive polymer matrix (acrylate vinyl acetate) is being widely used clinically for the treatment of moderate to severe cancer pain ([@b12-cia-3-421]; [@b77-cia-3-421]). The transdermal buprenorphine patch available in matrix form does not allow for dose dumping in the event of damage to the patch and also improves patient compliance, an extremely important factor in elderly patients ([@b64-cia-3-421]).

The purpose of the transdermal patch is to provide long-term pain relief and to avoid an increase in adverse side effects. The transdermal buprenorphine patch is available in 3 strengths, containing 20, 30, or 40 mg of buprenorphine, which can deliver 35, 52.5, or 70 μg/hour over 72 hours, respectively. It is generally recommended that patients who have not taken any analgesic or a nonopioid analgesic should start with a 35 μg/hour patch. This long-acting form of buprenorphine can be supplemented with the short-acting form of sublingual buprenorphine for breakthrough pain. If the patch is used, the time to minimum therapeutic concentration is 21 hours. After the placement of a transdermal patch additional analgesics should be available as needed for 24--48 hours for treatment of breakthrough pain, because plasma levels of buprenorphine rise slowly after patch application. All opioid-naïve patients, especially the elderly, should be started with the lowest strength patch.

Transdermal buprenorphine for treatment of chronic pain
=======================================================

Transdermal buprenorphine has been shown to be useful for the treatment of chronic pain associated with cancer as well as noncancer etiologies ([@b75-cia-3-421]). [@b53-cia-3-421] studied the analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain. They demonstrated that buprenorphine is an effective analgesic for chronic pain. It was shown that transdermal buprenorphine patches are useful for the treatment of moderate to severe cancer pain and also for noncancer pain that is severe and unresponsive to nonopioid analgesics. About one third of study patients with chronic pain had satisfactory analgesia with the administration of buprenorphine. In addition transdermal buprenorphine was found to decrease the need for rescue medications and increases the duration of pain-free sleep. [@b54-cia-3-421] also studied the efficacy and tolerability of long-term treatment with transdermal buprenorphine patients with chronic persistent pain of moderate to severe intensity who had previously received buprenorphine in 3 short-term clinical trials. They studied 134 patients with cancer-related pain and 105 patients with pain of noncancerous origin. The mean duration of participation was 7.5 months and the adherence to therapy was 78.7%. This level of adherence to therapy would be of particular help in the elderly.

Neuropathic pain or chronic persistent pain often presents as burning, lancinating pain caused by injury or chronic changes to peripheral or central nerves ([@b57-cia-3-421]) and has been found to be difficult to treat with conventional analgesics ([@b28-cia-3-421]). There is increasing evidence that opioids can decrease neuropathic pain in peripheral and central areas though the response can be variable ([@b69-cia-3-421]). For example morphine, a typical mu opioid agonist, is not very sensitive in treating neuropathic pain ([@b56-cia-3-421]). It has been suggested that the ineffectiveness of morphine in controlling neuropathic pain may be due to the downregulation of opioid receptors after nerve injury in the sensory neurons and in the spinal cord ([@b89-cia-3-421]). In contrast, buprenorphine, a stronger opioid, has been shown in rats and humans to be effective in controlling neuropathic pain. It is known that some opioids have an NMDA blocking effect. [@b25-cia-3-421], pp. 165--8) have shown that buprenorphine is one such opioid that can block NMDA receptors and reduce reflex facilitation and central sensitization ([@b51-cia-3-421]).

Mechanical and cold allodynia and hyperalgesia were alleviated in rats with neuropathic pain behaviors ([@b51-cia-3-421]). Human studies have also shown similar results. Intravenous buprenorphine has been shown to relieve long-term neuropathic pain in patients after thoracotomy ([@b5-cia-3-421]). In another study, phantom limb pain was relieved by intrathecal buprenorphine after amputation ([@b61-cia-3-421]). Buprenorphine given by the transdermal route has also providef adequate pain relief in cases of neuropathic pain, as shown in 3 patients with chronic nonmalignant pain due to musculoskeletal diseases ([@b3-cia-3-421]).

Transdermal buprenorphine has been used for "opioid rotation", which is a method to treat chronic pain refractory to treatment by other opioids for long-term pain relief. In a opioid rotation study ([@b29-cia-3-421]), 42 patients (mean age 64.1 years) receiving high-dose morphine (120--240 mg/day) for chronic pain secondary to neuropathic, musculoskeletal, or malignant etiology were switched to transdermal buprenorphine because of intolerable side effects and insufficient pain relief. The patients were followed for more than 10 weeks. Patients reporting very good pain relief increased from 5% to 75% and those reporting improved quality of sleep increased from 14% to 74%. There was no tolerance to buprenorphine via this route and only 11.9% of adverse effects were noted, mostly due to local irritation. Chronic pain of cancer and noncancer origin was also reported to be effectively treated in all ages \>70 years in another study by [@b36-cia-3-421], in which a total of 13,179 chronic pain patients were evaluated. In this study 28% had cancer pain and 72% had noncancer pain. No development of tolerance was seen clinically in these patients and the patches were well tolerated. In a randomized controlled study by [@b63-cia-3-421], patients with chronic cancer had better pain control, and improved mental health and vitality with the use of transdermal buprenorphine compared with sustained-release morphine. Transdermal buprenorphine appears to be well tolerated and effective for the treatment of chronic cancer and chronic noncancer pain in the long term.

Advantages in the elderly
=========================

Elderly patients need special consideration with several factors related to drug delivery, including drug delivery itself, drug interactions, and adherence to prescribed regimens. Transdermal drug delivery systems have advantages over other routes of drug administration especially in the elderly ([@b66-cia-3-421]). The transdermal route is suited for the elderly as it provides ease of use for the patient and the care-taker, provides greater adherence to prescribed regimens, and has less risk of toxicity and dose dumping. This is especially important because of the increased need for medications in older age when there is a higher incidence of chronic conditions such as chronic pain, diabetes mellitus, cardiovascular disease, and neurological diseases such as Parkinson's disease and Alzheimer's disease. A transdermal delivery system is also useful when elderly patients are unable to tolerate oral medications or are unwilling to swallow oral medications. Transdermal medications also avoid needle punctures associated with subcutaneous or intravenous routes and are less labor intensive than these routes ([@b45-cia-3-421]). It has been stated that transdermal delivery results in reasonably constant plasma drug concentrations because of its rate controlled delivery.

Transdermal buprenorphine has several advantages over the conventional methods of administration in the elderly: it results in no peak trough effects and a slower increase in serum concentration, resulting in fewer adverse events in serum concentrations compared with sublingual buprenorphine ([@b7-cia-3-421]; [@b46-cia-3-421]). The use of drugs with an absence of peak trough effects is in accordance with WHO guidelines, which recommend that to decrease adverse side effects, drugs should be used to treat chronic pain that do not induce sudden peaks in serum concentrations. The absorption of transdermal buprenorphine among patients varies less than among patients on transdermal fentanyl ([@b44-cia-3-421]). Transdermal fentanyl absorption has been thought to decrease in the elderly, resulting in many dose adjustments. Since the absorption of transdermal buprenorphine is little affected with age, its relative potency will increase in the elderly. It has been suggested that fewer dosage adjustments are needed in patients using transdermal buprenorphine compared with patients using transdermal fentanyl. This was shown in a retrospective analysis on data from 400 medical practices in Germany which showed a significantly greater increase in mean daily dosage in patients treated with transdermal fentanyl compared with patients treated with transdermal buprenorphine ([@b77-cia-3-421]). The painful conditions included cancer, osteoarthritis, low back pain, and osteoporosis.

The reduced need to escalate transdermal buprenorphine relative to transdermal fentanyl is probably related to the antihyperalgesic effect, which prevents or blocks hyperadaptive responses differing from fentanyl ([@b19-cia-3-421]; [@b2-cia-3-421]; [@b50-cia-3-421]). Incidence of chronic pain conditions increases with advancing age. Increased back pain due to osteoporotic and compression fractures are common in the elderly ([@b32-cia-3-421]) and transdermal buprenorphine, by virtue of its dosage stability, could be used to treat these conditions safely in the elderly.

The low incidence of adverse events associated with buprenorphine lends an added attraction for use in the elderly who have decreased tolerance to adverse effects. In the elderly the transdermal patch is ideal because it can be easily applied, resulting in greater compliance in this population who tend to be more forgetful. It also has a lower susceptibility to the development of toxicity and opioid abuse because it adheres strongly and is less susceptible to damage ([@b11-cia-3-421]).

Less respiratory depression
---------------------------

Because of its partial agonist activity and the associated ceiling effect in respiratory depression ([@b84-cia-3-421]), transdermal buprenorphine is useful for treatment in the elderly who are more prone to respiratory depression associated with common respiratory diseases such as chronic bronchitis, emphysema, and chronic obstructive pulmonary disease. [@b24-cia-3-421] studied 10 critically ill patients in whom intravenous buprenorphine 0.2--0.4 mg had no significant effect on base excess values, oxygen saturation, or heart rate. It did, however, increase the arterial carbon dioxide levels and reduce respiratory rate in these patients. A large study in 3,690 cancer patients (44% of whom were ≥70 years of age) clearly showed the effectiveness and safety of the transdermal buprenorphine patch in the elderly ([@b36-cia-3-421]).

Long duration of action
-----------------------

The high affinity to the mu receptor enables buprenorphine to exert its analgesic effect for a long duration, eliminating the need for daily dosing and overcoming problems of non-adherence to treatment regimens which is common in the elderly. This property will also decrease the risk of death by overdose.

Drug interactions in the elderly
================================

To establish specific safety guidelines, the use of buprenorphine in the elderly with other drugs requires further investigation, especially as many elderly patients are using many different pharmacological agents such as treatment for heart disease and cognitive dysfunction. Common medications of the elderly include beta blockers, statins, and ACE-inhibitors. Buprenorphine has been known to inhibit the cytochrome P 450 system by inhibiting the CYP3A4- and CYP2D6-mediated reactions. It is thought, however, that the clinical concentrations used are unlikely to affect significantly metabolism of drugs that are metabolized by cytochrome P 450 ([@b81-cia-3-421]). It is known than CYP3A4 and UCTiA3 are relatively preserved in the elderly. Drugs that interact with CYP3A4 will not prevent conjugation, which is rate limiting. Buprenorphine interacts with CYP3A4 differently than methadone. It is seem that fluvoxamine, which blocks CYP3A4 and methadone metabolism, does not interfere with buprenorphine clearance ([@b42-cia-3-421]).

Buprenorphine cannot be dialyzed and very high doses of naloxone are sometimes needed to reverse respiratory depression ([@b62-cia-3-421]; [@b49-cia-3-421]; [@b31-cia-3-421]), because of the high affinity of buprenorphine to the mu receptor as well as the slow dissociation from the receptor. Respiratory depression with the use of buprenorphine, except after the intraspinal route ([@b14-cia-3-421]), is very rare ([@b83-cia-3-421]). It must be remembered that concomitant exposure to other drugs that can induce or inhibit the enzyme may intensify the action of buprenorphine. Opioids, anesthetic agents, sedatives, hypnotics, monoamine oxidase inhibitors, antidepressants, neuroleptics, and alcohol can intensify the CNS effects of buprenorphine.

Disadvantages in the elderly
============================

To avoid opioid toxicity symptoms, buprenorphine should be used with caution when it is being used with other drugs such as benzodiazepines. This interaction with benzodiazepines can occur with all opioids and is related to the synergistic effect on the CNS causing sedation and respiratory depression. This effect is not due to hepatic metabolism ([@b41-cia-3-421]).

[@b52-cia-3-421] studied 21 buprenorphine-related deaths in Singapore. In 19 of these deaths buprenorphine and benzodiazepines were being used concurrently, suggesting that their concurrent use could be fatal. All these individuals were under the age of 40 years. Therefore, benzodiazepines should be prescribed with caution in the elderly. It has been reported that intravenous use of buprenorphine combined with benzodiazepines has resulted in some deaths ([@b68-cia-3-421]). In the event of respiratory depression when transdermal buprenorphine and benzodiazepines are used concurrently, the treatment would include respiratory support with mechanical ventilation if necessary until buprenorphine is completely metabolized.

Buprenorphine and drug dependence
=================================

Buprenorphone is licensed to treat drug dependence. In the large experience published, there are fewer deaths with buprenorphine maintenance therapy than with methadone. If a patient with cancer and opioid dependence or a history of drug abuse had pain, buprenorphine would be a reasonable choice in combination with naloxone.

Use in the presence of cognitive disorders
==========================================

In the elderly suffering from cognitive and motor deficits as a result of chronic neurological diseases such as Parkinson's disease and Alzheimer's disease, transdermal buprenorphine will be a useful tool for the administration of drugs when patients are forgetful, or unwilling or unable to swallow oral medications. Cumbersome equipment associated with the use of intravenous of subcutaneous infusions can also be avoided. Rate-controlled delivery through the transdermal route leads to constant plasma concentrations of the drug irrespective of the drug's half-life.

Buprenorphine is metabolized by the liver by glucuronidation and not oxidation, and should be used in caution with elderly patients with hepatic disease such as cirrhosis, though glucuronidation is less affected by liver disease than is oxidation of opioids. In patients with increased temperature, additional monitoring may be required since increased body temperature can increase skin permeability. Conditions where buprenorphine are contraindicated are patients with opioid dependence, myasthenia gravis, respiratory depression, and delirium tremens.

Future research
===============

In addition to cancer and arthritis, there are several chronic neuropathic pain syndromes that occur more commonly with advancing age. These include post-herpetic neuralgia ([@b9-cia-3-421]), diabetes, and strokes. Long-standing diabetes could lead to painful diabetic neuropathy, and strokes can be followed by post-stroke pain. The use of transdermal buprenorphine in these settings will require further evaluation.

Conclusion
==========

Chronic pain in the elderly is a significant problem and the age-related metabolic, cognitive, and pharmacokinetic changes associated with advanced age make pain control in the elderly a challenge. The transdermal buprenorphine matrix allows for slow release of buprenorphine, and damage does not produce dose dumping, which is an added advantage especially in the elderly ([@b11-cia-3-421]). The high incidence of coexisting diseases such as diabetes, cardiovascular, and neurological diseases in the elderly raises concerns of drug interactions with multiple medications. In addition the elderly need special consideration for adherence to medication regimen and drug delivery ([@b67-cia-3-421]). The recently developed transdermal buprenorphine, with its unique pharmacodynamics and special matrix formulation, shows promise for the control of this difficult problem in the elderly. The pharmacodynamics of buprenorphine shows that it has several advantages for use in the elderly. Scientific studies have significantly refuted misconceptions of buprenorphine in the past, such as the inability to produce adequate analgesia because of its partial agonist effect, the ineffectiveness of other opioids to act in the presence of buprenorphine, and the concern that if respiratory depression occurred it could not be reversed with naloxone. Recent scientific studies with buprenorphine have shown no evidence of a ceiling dose of analgesia in humans but only a ceiling effect for respiratory depression ([@b84-cia-3-421]), suggesting a low abuse liability and increased safety. Its mu agonist properties of long duration exist for analgesia, sedation, euphoria, and papillary constriction. Naloxone has been found to reverse any respiratory depression caused by buprenorphine ([@b31-cia-3-421]). The safe and effective use of transdermal buprenorphine in the presence of renal failure makes it an attractive choice for older individuals who have a higher predisposition for the development of renal insufficiency. In addition the low potential for drug to drug interaction along with the beneficial effects on the immune system makes it a suitable opioid for use in the elderly ([@b36-cia-3-421]). It must be remembered, however, that buprenorphine and transdermal buprenorphine could be associated with sedation and the elderly should be monitored carefully for this side effect. In addition buprenorphine should be used with caution with other drugs such as benzodiazepines. More outcome studies are needed on the effectiveness of transdermal buprenorphine for control of chronic pain associated with conditions more commonly seen in the elderly such as diabetic neuropathy, post-stroke pain, and post-herpetic neuralgia.
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